GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: ALKS
Neutral

Alkermes, Inc. (NASDAQ: ALKS) downgraded to Neutral by JP Morgan

Thursday,  Jan 21, 2016  5:25 PM ET by Kristen Bailey

JP Morgan downgraded Alkermes, Inc. (NASDAQ: ALKS) to
Neutral. JP Morgan rated Alkermes, Inc. (NASDAQ: ALKS) to Buy on 11/09/2007, when the price was $13.59.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy